News

Drug Reimbursement Recommendation - inotersen (Tegsedi)

Today, CADTH has issued final recommendations for:

inotersen (Tegsedi)

Indications: hereditary transthyretin amyloidosis
Recommendation: Reimburse with clinical criteria and/or conditions

For more information